Abramson Cancer Center Support Grant

项目摘要-艾布拉姆森癌症中心 宾夕法尼亚大学的艾布拉姆森癌症中心(ACC)是NCI指定的历史最悠久的癌症中心之一 综合性癌症中心。行政协调委员会服务于种族和经济多元化的集水区--12 宾夕法尼亚州、新泽西州和特拉华州的毗连县，约有700万居民。 我们集水区的居民面临着比全国其他地区更高的癌症发病率。 通过综合、动态和高影响力的研究计划，追求基础、临床和人口- 基于研究，ACC促进了开创性的科学发现，并促进了这些发现的翻译 将这些发现转化为临床实践，转变以患者为中心的癌症护理和癌症控制的范式。 ACC在宾夕法尼亚大学的三家成人医院和儿童医院提供非凡的癌症护理 费城。通过成为大学强大的学术生态系统的一部分，ACC进一步得到加强 宾夕法尼亚州。ACC的使命是减少我们整个集水区的癌症负担， 通过独特的综合、多产和全面的研究努力，为国家、国家和世界创造条件。我们的愿景 是一个杰出的以科学为导向、以患者为中心的综合性癌症中心，具有深刻的 持久的影响。ACC有324个成员、9个研究项目、9个共享资源和强大的 社区外展和参与团队、临床方案和数据管理、方案审查 和监测系统，癌症研究培训和教育，以及管理。在目前的资金中 在此期间，ACC成员发表了4,052篇手稿，并招募了22,000多名介入研究对象 试验和37,000多名非干预性试验的受试者。ACC成员每年直接持有1.701亿美元 其中1.032亿美元来自NIH，5920万美元来自NCI。行政协调委员会成员持有267 R01- 等价物。行政协调委员会的显著优势包括非凡的智力资本、独特的协作 推动翻译研究的文化，平衡而强大的研究组合，对我们的坚定承诺 集水区，以及一个为成人和儿童提供护理的现代化和不断扩大的癌症临床企业。 当前资助期间的主要成就包括免疫学、细胞科学方面的变革科学 生物学、生殖系遗传学和表观遗传学；临床试验的影响范围从长凳到旁观的发现 获得多项FDA批准，包括CAR T细胞的开发、翻译和FDA批准为第一个 癌症基因治疗；质子辐射和分子成像的新方法；全国领先的努力 戒烟和接种HPV疫苗；将黑人受试者参与临床试验的人数增加一倍；以及 领导力推动有关吸烟和含糖饮料的新健康政策。通过利用新的机构， 慈善和其他资源，ACC不断创新，以减轻我们的癌症负担 集水区内外，坚持不懈，全面严谨，改善生活 癌症患者和高危人群的健康状况。

PROJECT SUMMARY – Abramson Cancer Center The Abramson Cancer Center (ACC) at the University of Pennsylvania is one of the oldest NCI-Designated Comprehensive Cancer Centers. The ACC serves an ethnically and economically diverse catchment area – 12 contiguous counties in Pennsylvania, New Jersey, and Delaware, with approximately 7 million residents. Residents in our catchment area face significantly higher rates of cancer incidence than the rest of the country. Through integrated, dynamic, and high-impact Research Programs pursuing basic, clinical, and population- based research, the ACC fosters pioneering scientific discoveries and facilitates the translation of these discoveries into clinical practice, transforming paradigms of patient-centered cancer care and cancer control. ACC provides extraordinary cancer care at three Penn Medicine adult hospitals and Children's Hospital of Philadelphia. The ACC is further enhanced by being part of the powerful academic ecosystem of the University of Pennsylvania. The ACC mission is to reduce the burden of cancer throughout our catchment area, the nation, and the world through uniquely integrated, productive, and comprehensive research efforts. Our vision is to exemplify an exceptional science-driven, patient-focused comprehensive cancer center with deep and lasting impact. The ACC has 324 members, nine Research Programs, nine Shared Resources, and robust teams for Community Outreach and Engagement, Clinical Protocol and Data Management, Protocol Review and Monitoring Systems, Cancer Research Training and Education, and Administration. In the current funding period, ACC members published 4,052 manuscripts and enrolled more than 22,000 subjects on interventional trials and more than 37,000 subjects on non-interventional trials. ACC members hold $170.1M in annual direct funds, of which $103.2M comes from the NIH and $59.2M from the NCI. ACC members hold 267 R01- equivalents. Notable strengths of the ACC include extraordinary intellectual capital, a uniquely collaborative culture that drives translational research, a balanced and strong research portfolio, deep commitment to our catchment area, and a modern and expanding cancer clinical enterprise for the care of adults and children. Chief accomplishments in the current funding period include transformative science in immunology, cell biology, germline genetics, and epigenetics; clinical trials with impact ranging from bench-to-beside discovery to multiple FDA approvals, including development, translation, and FDA approval of CAR T cells as the first cancer gene therapy; novel approaches in proton radiation and molecular imaging; nation-leading efforts in smoking cessation and HPV vaccination; doubling of Black subjects' participation in clinical trials; and leadership driving new health policy around smoking and sugary beverages. By leveraging new Institutional, philanthropic, and other resources, the ACC continues to innovate to reduce the burden of cancer in our catchment area and beyond, relentlessly working in a comprehensive and rigorous fashion to improve the lives of cancer patients and those at risk.